The purpose of this study is to determine whether investigational ixazomib maintenance therapy improves survival in patients with newly diagnosed multiple myeloma who have had a major response to initial therapy and who have not had a stem cell transplant.
SparkCures ID | 830 |
---|---|
Trial Phase | Phase 3 |
Enrollment | 761 Patients |
Treatments |
|
Trial Sponsors |
|
NCT Identifier |
|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
Inclusion Criteria:
Exclusion Criteria:
Please visit the ClinicalTrials.gov page for historical site information.
View Centers